
The study analyzed data from 1253 patients across three RCTs comparing brolucizumab and aflibercept for diabetic macular edema (DME). Brolucizumab showed non-inferior improvements in best-corrected visual acuity (LSMD 0.29; p = 0.73) and significantly greater reductions in central subfield thickness (LSMD −24.5 μm; p < 0.05). Adverse event rates, including AESIs (RR 1.7; p = 0.08) and ocular AEs (RR 0.95; p = 0.45), were not significantly different between treatments. Results suggest brolucizumab as a promising alternative, though further RCTs are needed to confirm safety.
Like
Save
Share